---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Mechanism of action"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Mechanism of action. Topics: Mechanism: AAV5 vector carrying a microRNA that non-selectively lowers human huntingtin, Non-selective huntingtin knockdown: company description of the construct, miQURE platform: degradation of disease-causing transcripts and secondary exosome-mediated silencing, Mechanistic goals of the phase I/II studies: biodistribution and durable knockdown of huntingtin and exon 1 huntingtin, and 15 further topics. 19 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/mechanism-of-action"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Mechanism of action

<a id="heading-2.1.2.6.1"></a>

## 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

### Mechanism: AAV5 vector carrying a microRNA that non-selectively lowers human huntingtin

> “The vector acts as a delivery system and is based on a non-disease causing adeno-associated virus (AAV) that has been changed to carry and deliver a gene encoding a miRNA that will recognize, bind and non-selectively lower the human huntingtin protein.”
> “The therapeutic goal is to inhibit the production of the mHTT by using AAV to deliver genes encoding miRNA directly to the brain for non-selective (both mutant and normal) lowering of the huntingtin protein.”

Source: [uniQure Phase I/II clinical trial page](https://www.uniqure.com/programs-pipeline/phase-1-2-clinical-trial-of-amt-130)

<a id="topic-2.1.2.6.1-2"></a>

### Non-selective huntingtin knockdown: company description of the construct

> “AMT-130 comprises a recombinant AAV5 vector carrying a DNA cassette encoding a microRNA that non-selectively lowers or knocks-down human huntingtin protein in Huntington’s disease patients.”

Source: [uniQure press release, FDA Fast Track designation (2019)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-receives-fda-fast-track-designation-amt-130-gene-therapy)

<a id="topic-2.1.2.6.1-3"></a>

### miQURE platform: degradation of disease-causing transcripts and secondary exosome-mediated silencing

> “AMT-130 is a miQURE®-based gene-transcript silencing technology designed to degrade disease-causing gene transcripts without off-target toxicity while inducing silencing throughout the entire target organ through secondary exosome-mediated delivery.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

> “miQURE is designed to degrade disease-causing genes without off-target toxicity and induce silencing of the entire target organ through secondary exosome-mediated delivery.”

Source: [uniQure press release, preclinical publications (2021)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-publications-preclinical-data-amt-130)

<a id="topic-2.1.2.6.1-4"></a>

### Mechanistic goals of the phase I/II studies: biodistribution and durable knockdown of huntingtin and exon 1 huntingtin

> “biodistribution of the therapy in both the deep and cortical structures of the brain via transport of the AAV vector and through secondary exosome-mediated delivery”
> “safe, on-target and durable knockdown of HTT and exon 1 HTT.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-2.1.2.6.1-5"></a>

### Axonal transport of the vector to other brain regions affected by the disease

> “AMT-130 is axonally transported to other brain regions affected by HD”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

> “These data are consistent with prior studies and further demonstrate that AAV5 undergoes anterograde and retrograde axonal transport following infusion, resulting in broad transduction of the structures affected by Huntington’s disease.”

Source: [uniQure press release, preclinical publication (2019)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-publication-preclinical-data-amt-130)

<a id="topic-2.1.2.6.1-6"></a>

### Construct attributes stated by the sponsor: suppression of huntingtin and of the exon 1 isoform

> “Suppresses both HTT and the highly toxic exon-1 isoform”
> “Precision-delivery directly to diseased areas of the brain”
> “Minimizes systemic exposure of drug”

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-2.1.2.6.1-7"></a>

### Construct design: targeting of huntingtin exon 1 and total silencing of both alleles

> “In the first approach, total silencing of wild-type and mtHTT was achieved by targeting exon 1.”
> “Twenty-one miHTT variants were designed to target HTT exon 1.”
> “For the first time, we show that the therapeutic pri-miRNA scaffold influences HTT knock-down and guide strand processing in vivo.”

Source: [Miniarikova et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5014463/)

<a id="topic-2.1.2.6.1-8"></a>

### Scaffold selection and absence of passenger strand activity in vitro

> “miH12-135 was highly efficient and together with miH12-101 and miH12-451 did not produce any passenger strand.”

Source: [Miniarikova et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5014463/)

<a id="topic-2.1.2.6.1-9"></a>

### Suppression of mutant huntingtin aggregates and neuronal dysfunction in a lentiviral rat model

> “Our data demonstrated suppression of mutant HTT messenger RNA, which almost completely prevented mutant HTT aggregate formation, and ultimately resulted in suppression of DARPP-32-associated neuronal dysfunction.”
> “Ultimately, AAV5-delivered-miRNA-mediated HTT lowering did not cause activation of microglia or astrocytes suggesting no immune response to the AAV5 vector or therapeutic precursor sequences.”

Source: [Miniarikova et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5658675/)

<a id="topic-2.1.2.6.1-10"></a>

### Continuous microRNA expression after a single vector administration

> “Importantly, the AAV-delivered-miRNA-based gene therapy approach comprises continual expression of artificial miRNAs following a single administration of an AAV vector, resulting in long-term HTT lowering.”

Source: [Miniarikova et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5658675/)

<a id="topic-2.1.2.6.1-11"></a>

### Rationale for lowering huntingtin messenger RNA rather than the protein

> “miRNA-based lowering strategies are designed to lower HTT mRNA levels and thereby reduce the overall mutant HTT protein.”
> “The latter is crucial for assessment of tolerability of non-selective HTT lowering, in which case the remaining levels of endogenous HTT are relevant.”

Source: [Miniarikova et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6079476/)

<a id="topic-2.1.2.6.1-12"></a>

### Cell types transduced by AAV5 after intracranial injection

> “AAV1, AAV2, and AAV5 preferentially transduce neurons and astrocytes after intracranial injection, whereas AAV9 more efficiently transduces astrocytes after intravenous delivery.”

Source: [Miniarikova et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6079476/)

<a id="topic-2.1.2.6.1-13"></a>

### Off-target assessment in patient-derived neurons and astrocytes

> “Small RNA sequencing showed that mature miHTT was processed correctly without off-target passenger strand.”
> “No cellular microRNAs were dysregulated, indicating that endogenous RNAi machinery was unaffected by miHTT overexpression.”
> “qPCR validation of in silico-predicted off-target transcripts, next-generation sequencing, and pathway analysis confirmed absence of dysregulated genes due to sequence homology or seed-sequence activity of miHTT.”

Source: [Keskin et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6849441/)

<a id="topic-2.1.2.6.1-14"></a>

### Non-allele-selective lowering: tolerability of wild-type huntingtin reduction in humanized mice

> “Importantly, non-selective suppression of huntingtin was generally tolerated, however high dose AAV5-miHTT did induce astrogliosis.”
> “Finally, we also observed that potent reduction of wild type HTT (wtHTT) in Hu21 control mice was tolerated up to 7 months post-injection but may induce impairment of motor coordination and striatal atrophy.”
> “Taken together, our data suggests that in the context of HD, the therapeutic benefits of mHTT reduction may outweigh the potentially detrimental effects of wtHTT loss following non-selective HTT lowering.”

Source: [Caron et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7145682/)

<a id="topic-2.1.2.6.1-15"></a>

### Non-allele-selective lowering: unknown consequences in adults stated to trial participants

> “AMT-130 lowers both normal and mutant huntingtin protein in animals. The effects of lowering normal and mutant huntingtin protein levels in adults are currently unknown.”

Source: [uniQure Phase I/II clinical trial page](https://www.uniqure.com/programs-pipeline/phase-1-2-clinical-trial-of-amt-130)

<a id="topic-2.1.2.6.1-16"></a>

### Extracellular vesicle-mediated spread of the therapeutic microRNA between cells

> “Preclinical studies demonstrate the brain-wide spread of AAV5-miHTT following a single intrastriatal injection, which is partly mediated by neuronal transport.”
> “Transfer of miHTT to recipient (HEK-293T, HeLa, and HD patient-derived neurons) cells was observed, which significantly reduced HTT mRNA levels.”
> “In summary, we provide evidence that an engineered miRNA”
> “is loaded into EVs, transported across extracellular space, and taken up by neighboring cells, and importantly, that miHTT is active in recipient cells downregulating HTT expression.”

Source: [Morais et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9455173/)

<a id="topic-2.1.2.6.1-17"></a>

### Two routes of spread from the injection site: axonal transport and vesicle transport

> “(ii) The AAV is then transported to distant brain regions (e.g., the cortex) via axonal anterograde/retrograde transport.”
> “(iii) Because of its miR-451 scaffold, miHTT is actively and preferentially loaded into EVs, resulting in intercellular transport of miHTT, independently of neuronal connections, to adjacent cells.”

Source: [Morais et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9455173/)

<a id="topic-2.1.2.6.1-18"></a>

### Exon 1 huntingtin protein as a target: N-terminal fragments and aberrant splicing

> “Various mechanisms lead to the production of N-terminal Huntingtin protein fragments, which are reportedly more toxic than the full-length protein.”
> “Consistently accumulating evidence indicates that small N-terminal fragments containing extended polyQ tracts significantly contribute mHTT cellular mislocalization, aggregation and toxicity.”
> “AMT-130 is an AAV5-delivered miRNA which is administered through a one-time intrastriatal injection.”

Source: [van der Bent et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9532260/)

<a id="topic-2.1.2.6.1-19"></a>

### Target sequence present in both full-length and exon 1 huntingtin transcripts

> “We have developed an engineered microRNA targeting the HTT exon 1 sequence (miHTT), delivered via adeno-associated virus serotype 5 (AAV5). The target sequence of miHTT is present in both FL HTT and HTT1a transcripts.”

Source: [Sogorb-Gonzalez et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11629698/)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
